1. Allegrezza S, Guard-Rauchs A (1999) The determinants of trademark deposits: an econometric investigation (a case study of the BENELUX). Econ Appl 2:51–68
2. AstraZeneca (2008) AstraZeneca settles US Nexium patent litigation with Ranbaxy.
http://www.astrazeneca.com/Media/Press-releases/Article/20080415--AstraZeneca-Settles-US-Nexium-Patent-Litigation-with-
. Accessed 8 Aug 2011
3. Atherly A (2009) The cost-effectiveness of direct-to-consumer advertising for prescription drugs. Med Car Res Rev 66(6):639–657
4. Berndt ER, Kyle M, Ling D (2003) The long shadow of patent expiration. Generic entry and Rx-to-OTC switches. In: Feenstra RC, Shapiro MD (eds) Scanner data and price indexes. University of Chicago Press, Chicago
5. Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E (2007) Authorized generic drugs, price competition, and consumers’ welfare. Heal Aff 26(3):790–799